Detection methods for microRNAs in clinic practice

Planell-Saguer, Mariàngels de; Rodicio, Marı́a Celina

doi:10.1016/j.clinbiochem.2013.02.017

Cited by 132 publications

(128 citation statements)

References 83 publications

Supporting

Mentioning

120

Contrasting

Unclassified

Order By: Relevance

“…These molecules are responsible for the regulation of various physiological processes and alterations in their expression levels can reflect different pathological conditions. Moreover, miRNAs are stable, and they can be quantified by different molecular techniques (32,33), such as qRT-PCR (33,34). Due to their diagnostic potential, miRNAs were evaluated as biomarkers in several pathological conditions like infectious diseases (38,39).…”

Section: Discussionmentioning

confidence: 99%

Characterization of MicroRNA Expression Profiles and Identification of Potential Biomarkers in Leprosy

et al. 2017

View full text Add to dashboard Cite

Leprosy is an important cause of disability in the developing world. Early diagnosis is essential to allow for cure and to interrupt transmission of this infection. MicroRNAs (miRNAs) are important factors for host-pathogen interaction and they have been identified as biomarkers for various infectious diseases. The expression profile of 377 microRNAs were analyzed by TaqMan low-density array (TLDA) in skin lesions of tuberculoid and lepromatous leprosy patients as well as skin specimens from healthy controls. In a second step, 16 microRNAs were selected for validation experiments with reverse transcription-quantitative PCR (qRT-PCR) in skin samples from new individuals. Principal-component analysis followed by logistic regression model and receiver operating characteristic (ROC) curve analyses were performed to evaluate the diagnostic potential of selected miRNAs. Four patterns of differential expression were identified in the TLDA experiment, suggesting a diagnostic potential of miRNAs in leprosy. After validation experiments, a combination of four miRNAs (miR-101, miR-196b, miR-27b, and miR-29c) was revealed as able to discriminate between healthy control and leprosy patients with 80% sensitivity and 91% specificity. This set of miRNAs was also able to discriminate between lepromatous and tuberculoid patients with a sensitivity of 83% and 80% specificity. In this work, it was possible to identify a set of miRNAs with good diagnostic potential for leprosy.KEYWORDS biomarker, leprosy, miRNA L eprosy is a chronic infectious disease caused by the bacillus Mycobacterium leprae. The infection affects primarily the skin and can cause damage to peripheral nerves, mucosa, and other organs, including liver and eyes. Leprosy is classified as a neglected tropical disease and remains one of the main causes of disability in the world (1-3). According to a World Health Organization (WHO) report including data from 138 countries, 211,974 newly diagnosed patients were notified in the year 2015 and 96% of them were reported from 22 countries, including Brazil (4).Leprosy presents a spectrum of clinical manifestations depending on the host immune response against M. leprae. It can be classified according to histopathological (Ridley-Jopling) criteria into different forms across two opposing poles: a so-called resistance pole responsible for a localized form of the disease (tuberculoid tuberculoid [TT]) and a susceptibility pole that is a disseminated form, which leads to the development of more severe clinical manifestations (lepromatous leprosy [LL]). There are also three intermediate and unstable forms: borderline tuberculoid (BT), borderline

show abstract

Section: Discussionmentioning

confidence: 99%

Characterization of MicroRNA Expression Profiles and Identification of Potential Biomarkers in Leprosy

et al. 2017

View full text Add to dashboard Cite

show abstract

“…In fact, because circulating miRNAs were recognized as promising biomarkers, many efforts were directed toward the development of fast and reliable detection methods. In particular, several diagnostic methods based on fast real-time polymerase chain reaction were developed 120 to be used as a stand-alone technique or in conjunction with technological platforms, such as those using primers on multi-well plates or microfluidic cards exploiting nanotechnologies to prefilter the samples. 121 These latter technologies were also proposed in association with microarrays.…”

Section: Circulating Mirnas As Biomarkers After Coronary Angioplastymentioning

confidence: 99%

MicroRNAs for Restenosis and Thrombosis After Vascular Injury

Gareri

Rosa

Indolfi

2016

Circulation Research

109

View full text Add to dashboard Cite

Percutaneous revascularization revolutionized the therapy of patients with coronary artery disease. Despite continuous technical advances that substantially improved patients' outcome after percutaneous revascularization, some issues are still open. In particular, restenosis still represents a challenge, even though it was dramatically reduced with the advent of drug-eluting stents. At the same time, drug-eluting stent thrombosis emerged as a major concern because of incomplete or delayed re-endothelialization after vascular injury. The discovery of microRNAs revealed a previously unknown layer of regulation for several biological processes, increasing our knowledge on the biological mechanisms underlying restenosis and stent thrombosis, revealing novel promising targets for more efficient and selective therapies. The present review summarizes recent experimental and clinical evidence on the role of microRNAs after arterial injury, focusing on practical aspects of their potential therapeutic application for selective inhibition of smooth muscle cell proliferation, enhancement of endothelial regeneration, and inhibition of platelet activation after coronary interventions. Application of circulating microRNAs as potential biomarkers is also discussed. (Circ Res.

show abstract

“…[8][9][10][11][12][13][14][15][16][17][50][51][52][53][54][55] Reliable quantification of mRNA and microRNA levels for diagnostic and prognostic purposes requires optimal RNA quality and quantity. However, the different instances along the RNA and miRNA analysis workflow can lead to length, sequence, and structure-specific biases in the final expression analysis of a given set of small RNAs.…”

Section: Challenges Faced By the Main Technologies In Nucleic Acmentioning

confidence: 99%

“…Equipment and analysis costs, throughput, and normalization 6,7 still represent obstacles for large-scale nucleic acid biomarker validation [8][9][10][11][12][13][14] and adoption in the clinics [15][16][17] Differences in the nucleic acid purification method, detection technology, and laboratory protocol often lead to different profiling results. Consequently, interpretation of differential expression data and comparisons across different studies has to be done with a note of caution, as standard deviations can span several orders of magnitude.…”

Section: Introductionmentioning

confidence: 99%

Future microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine

et al. 2016

View full text Add to dashboard Cite

Nucleic acid biomarkers have enormous potential in non-invasive diagnostics and disease management. In medical research and in the near future in the clinics, there is a great demand for accurate miRNA, mRNA, and ctDNA identification and profiling. They may lead to screening of early stage cancer that is not detectable by tissue biopsy or imaging. Moreover, because their cost is low and they are non-invasive, they can become a regular screening test during annual checkups or allow a dynamic treatment program that adjusts its drug and dosage frequently. We briefly review a few existing viral and endogenous RNA assays that have been approved by the Federal Drug Administration. These tests are based on the main nucleic acid detection technologies, namely, quantitative reverse transcription polymerase chain reaction (PCR), microarrays, and next-generation sequencing. Several of the challenges that these three technologies still face regarding the quantitative measurement of a panel of nucleic acids are outlined. Finally, we review a cluster of microfluidic technologies from our group with potential for point-of-care nucleic acid quantification without nucleic acid amplification, designed to overcome specific limitations of current technologies. We suggest that integration of these technologies in a modular design can offer a low-cost, robust, and yet sensitive/selective platform for a variety of precision medicine applications.

show abstract

Detection methods for microRNAs in clinic practice

Cited by 132 publications

References 83 publications

Characterization of MicroRNA Expression Profiles and Identification of Potential Biomarkers in Leprosy

Characterization of MicroRNA Expression Profiles and Identification of Potential Biomarkers in Leprosy

MicroRNAs for Restenosis and Thrombosis After Vascular Injury

Future microfluidic and nanofluidic modular platforms for nucleic acid liquid biopsy in precision medicine

Contact Info

Product

Resources

About